Project Grant R44DK148354
Award Date 8/11/26
Completion Date 7/31/28
Dollars Obligated $1M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77079, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $820,451 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the pharmacogenetics of weight cycling following discontinuation of GLP-1 receptor agonist therapy. The award funds a clinical trial in Houston that enrolls 100 obese adults to identify mechanisms underlying heterogeneous...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Delphi Stem, Inc. $306,863 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a framework for evaluating type 2 diabetes medication efficacy using patient-derived cellular models. The recipient will generate personalized islet-like aggregates from patient cells to predict drug responsiveness and tailor treatment regimens, with the goal of improving...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $308,000 to the Regents of the University of Minnesota on February 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a pilot clinical trial investigating SGLT2 inhibitor therapy in islet autotransplant recipients. The trial gathers preliminary data on the efficacy and safety of SGLT2 inhibitor therapy in patients who have undergone total pancreatectomy with islet...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas Southwestern Medical Center $295,649 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate adipocyte FGF1 signaling in systemic metabolism. The research examines fibroblast growth factor 1 (FGF1) as a potential lipid-lowering therapeutic target for hyperlipidemia and related metabolic disorders. Preliminary studies...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Baylor Research Institute $306,441 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a pilot randomized clinical trial assessing the feasibility, safety, and efficacy of rapid, simultaneous therapy initiation in patients with concurrent chronic kidney disease and type 2 diabetes (RAPID-CKD). The trial evaluates a protocolized approach to...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Pupil Bio, Inc. $1,015,056 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop an early detection test for Type 1 Diabetes using next-generation sequencing analysis of B cell-specific methylation patterns in cell-free DNA. Pupil Bio will refine marker selection to identify methylation patterns ultra-specific to pancreatic islet B cells, building...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Wayne State University $1.137 million on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to establish a database characterizing phosphorylation and O-linked N-acetylglucosamine (O-GlcNAc) glycosylation differences in skeletal muscle tissue between insulin-sensitive and insulin-resistant individuals. The research examines crosstalk between reversible...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $840,284 to the Trustees of Indiana University (doing business as Indiana University Indianapolis) on June 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Project Grant R01DK145079) to investigate molecular mechanisms of cross-talk between insulin and glucagon signaling in hepatic metabolism and to develop ultra-stable bihormonal insulin-glucagon fusion proteins....
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University $1,612,354 on September 13, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate pathogenic mechanisms linking intestinal microbial fermentation, adipose tissue metabolism, and cardiometabolic disease in obese youth with insulin resistance. The research will examine how insulin resistance impairs the protective metabolic responses triggered...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $178,000 to Beckman Research Institute of The City of Hope on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how the native pancreatic microenvironment regulates human islet cell function in health and type 1 diabetes. The research employs human pancreatic tissue slices to preserve native cellular architecture and directly compares hormone...